Herpes zoster ophthalmicus (HZO) secondary to platelet-rich plasma (PRP) therapy - A case report.
| Autor: | Zeineddine R; Assistance Publique - Hopitaux de Paris, Lariboisière Hospital, France., Abou Khater D; Assistance Publique - Hopitaux de Paris, Lariboisière Hospital, France., Mouawad Y; Assistance Publique - Hopitaux de Paris, Lariboisière Hospital, France., Hamieh C; Lebanese American University Medical Center, Lebanon., El-Hussein M; GHI Montfermeil Hospital, France. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heliyon [Heliyon] 2023 Nov 29; Vol. 9 (12), pp. e22815. Date of Electronic Publication: 2023 Nov 29 (Print Publication: 2023). |
| DOI: | 10.1016/j.heliyon.2023.e22815 |
| Abstrakt: | Androgenetic alopecia (AGA) is a common and benign cause of chronic hair loss that affects both males and females. Platelet-rich plasma (PRP) is a safe and minimally invasive technique with promising outcomes in patients with AGA, alongside other therapeutics use. The currently available data in the literature assures that the rate of side effects is low but includes infection and localized reaction (Stevens and Khetarpal, Feb. 2019) [1]. This article describes a case of herpes zoster ophthalmicus (HZO) following PRP treatment for androgenic alopecia, while shedding light on the importance of respecting the guidelines when injecting PRP therapy to ensure a safe outcome with no complications. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 Published by Elsevier Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|